Bioinformatics Analysis Raises Candidate Genes in Blood for Early Screening of Parkinson's Disease

Parkinson＇s disease （PD） is a typical degenerative disease, which is characterized by the most obvious symptoms of movement dysfunction, including shaking, rigidity, slowness of movement and difficulty in walking and gait. This disease can not be clearly identified through laboratory tests at present, thus application of high-throughput technique in studying the expression profiles of PD helps to find the genetic markers for its early diagnosis. Studies on expression profiles of neurodegenerative diseases have revealed the novel genes and pathways involved in the progress of illness. In this study, the expression profiles of PD in blood were compared, showing that 181 differentially expressed genes （DEG） exhibit a similar expression trend both in patients and in normal controls.

Results of National Colorectal Cancer Screening Program in Croatia(2007-2011)

AIM:To study the epidemiologic indicators of uptake and characteristic colonoscopic findings in the Croatian National Colorectal Cancer Screening Program.METHODS:Colorectal cancer(CRC) was the second leading cause of cancer mortality in men(n = 1063,49.77/100 000),as well as women(n = 803,34.89/100 000) in Croatia in 2009.The Croatian National CRC Screening Program was established by the Ministry of Health and Social Welfare,and its implementation started in September,2007.The coordinators were recruited in each county institute of public health with an obligation to provide fecal occult blood testing(FOBT) to the participants,followed by colonoscopy in all positive cases.The FOBT was performed by hypersensitive guaiac-based Hemognost card test(Biognost,Zagreb).The test and short questionnaire were delivered to the home addresses of all citizens aged 50-74 years consecutively during a 3-year period.Each participant was required to complete the questionnaire and send it together with the stool specimen on three test cards back to the institute for further analysis.About 4% FOBT positive cases are expected in normal risk populations.A descriptive analysis was performed.RESULTS:A total of 1 056 694 individuals(born between 1933-1945 and 1952-1957) were invited to screening by the end of September 2011.In total,210 239(19.9%) persons returned the envelope with a completed questionnaire,and 181 102 of them returned it with a correctly placed stool specimen on FOBT cards.Until now,12 477(6.9%),FOBT-positive patients have been found,which is at the upper limit of the expected values in European Guidelines for Quality Assurance in CRC Screening and Diagnosis [European Union(EU) Guidelines].Colonoscopy was performed in 8541 cases(uptake 66%).Screening has identified CRC in 472 patients(5.5% of colonoscopied,3.8% of FOBT-positive,and 0.26% of all screened individuals).This is also in the expected range according to EU Guidelines.Polyps were found and removed in 3329(39% of colonoscopied) patients.The largest number of polyps were found in the left half of the colon:64%(19%,37% and 8% in the rectum,sigma,and descendens,respectively).The other 36% were detected in the proximal part(17% in the transverse colon and 19% in ceco-ascending colon).Small polyps in the rectum(5-10 mm in diameter),sigmoid and descending colon were histologically found to be tubular adenomas in 60% of cases,with a low degree of dysplasia,and 40% were classified as hyperplastic.Polyps of this size in the transverse or ceco-ascending colon in almost 20% had a histologically villous component,but still had a low degree of dysplasia.Polyps sized 10-20 mm in diameter were in 43% cases tubulovillous,and among them,32% had areas with a high degree of dysplasia,especially those polyps in the cecoascending or transverse part.The characteristics of the Croatian CRC Screening National Program in the first 3 years were as follows:relatively low percentage of returned FOBT,higher number of FOBT-positive persons but still in the range for population-based programs,and higher number of pathologic findings(polyps and cancers).CONCLUSION:These results suggest a need for intervention strategies that include organizational changes and educational activities to improve awareness of CRC screening usefulness and increase participation rates.

Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening:A meta-analysis

AIM:To present a critical discussion of the efficacy of the faecal pyruvate kinase isoenzyme type M2(faecal M2-PK) test for colorectal cancer(CRC) screening based on the currently available studies.METHODS:A literature search in PubMed and Embase was conducted using the following search terms:fecal Tumor M2-PK,faecal Tumour M2-PK,fecal M2-PK,faecal M2-PK,fecal pyruvate kinase,faecal pyruvate kinase,pyruvate kinase stool and M2-PK stool.RESULTS:Stool samples from 704 patients with CRC and from 11 412 healthy subjects have been investigated for faecal M2-PK concentrations in seventeen independent studies.The mean faecal M2-PK sensitivity was 80.3%;the specificity was 95.2%.Four studies compared faecal M2-PK head-to-head with guaiacbased faecal occult blood test(gFOBT).Faecal M2PK demonstrated a sensitivity of 81.1%,whereas the gFOBT detected only 36.9% of the CRCs.Eight independent studies investigated the sensitivity of faecal M2-PK for adenoma(n = 554),with the following sensitivities:adenoma < 1 cm in diameter:25%;adenoma > 1 cm:44%;adenoma of unspecified diameter:51%.In a direct comparison with gFOBT of adenoma > 1 cm in diameter,47% tested positive with the faecal M2-PK test,whereas the gFOBT detected only 27%.CONCLUSION:We recommend faecal M2-PK as a routine test for CRC screening.Faecal M2-PK closes a gap in clinical practice because it detects bleeding and nonbleeding tumors and adenoma with high sensitivity and specificity.

Risks and challenges of HIV infection transmitted via blood transfusion

Promoting biosafety regulations and techniques supports human health and protects individuals and groups from harmful incidents.Particular attention should be paid to those potential infectious hazards associated with blood and other bodily fluids,especially those highly transmitted infectious diseases,such as human immunodeficiency virus(HIV),one of the largest global health threats.Ensuring innovative and adaptive screening and laboratory techniques to reduce the possibility of HIV transmission are integral to managing the disease.We review here the evolution and success of blood screening techniques for HIV,along with current issues that still need to be addressed.Published academic articles and media reports about nosocomial HIV transmission events since 1981 were reviewed to identify current blood screening and transfusion safety trends across the globe,along with specific recommendations from the Chinese perspective.Although most initial screening was limited only to antibody and antigen testing,newer screening tests(such as nucleic acid testing),coupled with risk-based screening of donors,have led to reduced risk of HIV transmission and continues to reduce the“window period,”when an HIV-positive individual may test negative though they have been infected.Further examination of current guidelines and regulations across the globe are discussed,in order to understand where critical gaps in screening may exist.Through examination of this data,it is evident that huge strides have been made since the beginning of the epidemic;however improved technical training of staff and streamlined testing guidelines could help promote efficient screening of HIV,while also supporting those providing care.

A β-sheet-targeted theranostic agent for diagnosing and preventing aggregation of pathogenic peptides in Alzheimer’s disease

Amyloid-βpeptide(Aβ)aggregates,particularly Aβoligomers,are established biomarker and toxic species in Alzheimer’s disease(AD).Early detection and disaggregation of Aβaggregates are of great importance for the treatment of AD due to the unavailability of therapy at the advanced stages of the disease.A multitalented agent,2-{2-[(1 H-benzoimidazol-2-yl)methoxy]phenyl}benzothiazole(BPB),is designed by merging twoβ-sheet targeting groups into one molecule to detect and inhibit the Aβaggregation.BPB can quantitatively measure theβ-sheet level of soluble Aβoligomers and specifically distinguish the aggregates of Aβ40 and Aβ42 by unique luminescence spectrum.Animal tests demonstrate that BPB can efficiently penetrate the blood brain barrier and precisely stain Aβplaques in the brain;more importantly,it can differentiate the blood of APP transgenic mice from that of normal ones.In addition to the diagnostic potential,BPB also suppresses the generation of ROS,protects the neurons from neurotoxicity,and disaggregates the Aβaggregates in brain homogenates of APP transgenic mice induced by metal ions or self-assembly.In view of its detective ability toward Aβoligomers and inhibition to Aβ-related neurotoxicity,BPB may be developed into a sensitive probe for screening blood samples in the early diagnosis of AD as well as an effective inhibitor for diminishing Aβaggregates in the treatment of the disease.